A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women

Pharmacokinetics Clinical Trial

Official title:

An Open-Label, Single-Dose, Randomized, 2-Treatment, 2-Period Crossover Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings 20% (w/w) in Postmenopausal Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02092571
• Other study ID #: DR201-BE-10021
• Status: Completed
• Phase: Phase 1
• Start date: February 2014
• Est. completion date: August 2014

Study information

• Verified date: November 2021
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study to assess the pharmacokinetics of 2 progesterone vaginal rings in postmenopausal women

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: August 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 40 Years to 70 Years

Eligibility

Inclusion:

1. Naturally postmenopausal woman with an intact uterus, 40 to 70 years of age, inclusive.

2. The subject has serum estradiol and FSH levels that are consistent with the subject being postmenopausal.

3. The subject has no clinically significant abnormality findings observed during pelvic, breast, and vaginal examination or based on mammogram and Pap smear evaluations.

4. The subject will agree to be treated with 1 mg/day estradiol oral tablets for at least 28 days before insertion of the first vaginal ring and throughout the study.

Exclusion:

1. The subject has a history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, urologic, gynecologic, immunologic, dermatologic, neurologic, or psychiatric disease.

2. The subject has a history of toxic shock syndrome.

3. The subject has a history of jaundice associated with previous use of oral contraceptives.

4. The subject has contraindications to the use of estrogen or progesterone that include, but are not limited to, the following:

• known sensitivity to estrogen or progesterone or related drugs

• known hypersensitivity to study medication ingredients, including FD&C Yellow No. 5 (tartrazine) present in estradiol tablets

• undiagnosed vaginal bleeding or high risk for endometrial cancer

• breast mass on examination

• known, suspected, or family history of estrogen- or progesterone-dependent neoplasia (now or in the past)

5. The subject has low-grade squamous intraepithelial lesion (LSIL) or worse as observed in the Pap smear at screening. Any other abnormal finding on the Pap smear that the investigator considers clinically significant (such as atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion [HSIL; ASC-H], atypical glandular cells [AGC]); or any Pap result that would necessitate further evaluation by biopsy and/or colposcopy.

6. The subject has any abnormal finding or condition deemed clinically significant by the investigator at screening that is a contraindication to the use of progestins, estrogen, or a vaginal ring.

7. The subject has a positive pregnancy test at screening or at any time during the study.

8. Current treatment with progesterone, other progestins, or estrogen (other than estradiol 1-mg tablets, progesterone 200-mg capsules, or medroxyprogesterone acetate 10-mg tablets required for this study purpose).

9. Use of any of the following medications within the time frames noted below before the start of estrogen treatment:

• vaginal hormonal products (rings, creams, or gels) within 7 days

• transdermal estrogen alone or estrogen/progestin products within 28 days

• oral estrogen or progestin therapy within 56 days

• intrauterine progestin therapy within 56 days

• progestin implants or estrogen alone injectable drug therapy within 3 months

• estrogen pellet therapy or progestin injectable therapy within 6 months

10. The subject has a vaginal ultrasonography at screening that confirms an active endometrial lining and/or an endometrial thickness of =4 mm.

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• Progesterone vaginal ring,
Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)

Locations

Country	Name	City	State
United States	Teva Investigational Site 12355	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	baseline-adjusted AUCt		16 weeks
Primary	baseline-adjusted AUC8		16 weeks
Primary	baseline-adjusted Cmax		16 weeks
Secondary	baseline-adjusted tmax		16 weeks
Secondary	baseline-unadjusted AUCt		16 weeks
Secondary	baseline-adjusted ?z		16 weeks
Secondary	baseline-adjusted t½		16 weeks
Secondary	baseline-unadjusted AUC8		16 weeks
Secondary	baseline-unadjusted Cmax		16 weeks
Secondary	baseline-unadjusted tmax		16 weeks
Secondary	baseline-unadjusted ?z		16 weeks
Secondary	baseline-unadjusted t½		16 weeks